Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30229391 | 1.00 | MDM4 (0.45) | MDM4TP53MDM2MAPTSMN1; SMN2 | |
| SCHEMBL29221359 | 0.91 | MDM4 (0.44) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL30229941 | 0.91 | MDM4 (0.44) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL29633683 | 0.90 | MDM4 (0.48) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL24899356 | 0.90 | TACR1 (0.45) | MDM4TP53MDM2MAPTSMN1; SMN2 | |
| SCHEMBL30229467 | 0.90 | TACR1 (0.45) | MDM4TP53MDM2MAPTSMN1; SMN2 | |
| SCHEMBL29221390 | 0.88 | MDM2 (0.52) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL30229498 | 0.88 | MDM2 (0.52) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL31210294 | 0.88 | MDM2 (0.52) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL25658030 | 0.88 | MDM2 (0.52) | MDM4TP53MDM2CASP3SLC17A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023288213-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-01-19 | — | — | WO | disclosed |